<DOC>
	<DOCNO>NCT01220570</DOCNO>
	<brief_summary>This clinical trial evaluate whether treatment ridaforolimus , dalotuzumab , ridforolimus/dalotuzumab combination therapy reduce Growth Factor Signature ( GFS ) Score among participant breast cancer .</brief_summary>
	<brief_title>The Growth Factor Signature ( GFS ) Intermediate Biomarker Response Development PI3K-Pathway Inhibitors Patients With Breast Cancer ( MK-8669-050 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Participant operable Stage IIIIa invasive breast cancer follow subtype : ERpositive , HER2negative tumor histologic grade 2 3 Ki67 â‰¥ 15 % Tumor least 2 cm diameter assess physical radiographic exam Participant consent provide exist tissue sample core needle biopsy drug administration Participant consent provide tissue sample follow drug administration second core needle biopsy surgical specimen Participant must adequate organ function Participant receive prior chemotherapy , biological therapy radiotherapy breast cancer Participant know hypersensitivity component study drug analog , include hypersensitivity macrolide antibiotic ( e.g . clarithromycin , erythromycin , azithromycin ) . Participant poorly control diabetes mellitus , require insulin glucose control . Participant unable swallow capsule and/or absorb oral medication Participant pregnant breastfeeding , expect conceive child within project duration study . Participant known Human Immunodeficiency Virus ( HIV ) positive Participant know history active Hepatitis B C. Participant concurrently use growth hormone ( GH ) growth hormone inhibitor Participant significant uncontrolled cardiovascular disease , include heart failure , unstable angina , myocardial infarction within last 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ridaforolimus</keyword>
	<keyword>ridaforolimus/dalotuzumab combination therapy</keyword>
</DOC>